Maximum quantity allowed is 999
请选择数量
Leucine Rich-Repeat Kinase (LRRK) Inhibitors
The LRRK2 is a large protein (2527 amino acids) with serine-threonine (Ser/Thr) protein kinase activity and autophosphorylation activity. It is highly expressed in many mammal tissues. Genetic mutations in the G2019S encoding portion of LRRK2 (LRRK2-G2019S) have been detected frequently in Parkinson's (PD) patients.1) As a result, LRRK2-G2019S is a promising therapeutic target for the treatment of PD, and its inhibitors have been used as useful tools in PD research.2,3,4) For more information, please refer to the application information of product detail page on our website.
Figure. Schematic of LRRK2 protein domain structure with reported PD pathogenic familial mutations sites (red).1)
References
- 1) Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors
- 2) Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models
- 3) CHAPTER 11: LRRK2 Kinase Inhibitors as New Drugs for Parkinson’s Disease?
- 4) Chapter Two - Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease
![Anthra[1,9-cd]pyrazol-6(2H)-one](/medias/A2548.jpg?context=bWFzdGVyfHJvb3R8NDAyNjd8aW1hZ2UvanBlZ3xhRFEwTDJneE1TODRPVEk0TkRRMU9USXpNelU0TDBFeU5UUTRMbXB3Wnd8YzgzMjEwNmI0ZDMzODBmYmFmMzQ4ZjJkNmQ4NmRhMjAwMWQ3MTUzYTJlNTg2ZTlmMDIyOGM5NTZkZTAxYzVjNw "Anthra[1,9-cd]pyrazol-6(2H)-one")
添加到您的購物車
Product Availability by Store Location
Hours